
Which companies have agreed to drop artificial food dyes?
(NEXSTAR) — Dozens of companies that make ice cream and frozen dairy desserts announced on Monday that they would remove artificial food dyes from their products by 2028, marking yet another voluntary move away from such food coloring within the food industry.
It comes in response to a mission set forth by Health and Human Services Secretary Robert F. Kennedy Jr. to remove the artificial additives.
Why are companies ditching artificial dyes?
In April, Food and Drug Administration Commissioner Marty Makary said the agency would move to eliminate several synthetic dyes by the end of next year. That includes Green 3, Red 40, Yellow 5, Yellow 6, Blue 1, and Blue 2. Red 3 was set to be banned in food by 2027 because it caused cancer in laboratory rats; the FDA called for that deadline to move up.
A new Texas law could have wider effect on how food products are made, experts suggest
The agency is relying largely on voluntary efforts by food manufacturers but also plans to establish a standard and timeline for the food industry to switch to natural alternatives and revoke authorization for dyes not in production. Additionally, the FDA said it would authorize four new natural color additives.
Which companies have said they'll stop using dyes?
Many U.S. food companies are already reformulating their foods, according to Sensient Colors, one of the world's largest producers of food dyes and flavorings. In place of synthetic dyes, foodmakers can use natural hues made from beets, algae and crushed insects and pigments from purple sweet potatoes, radishes and red cabbage.
Among those that have recently announced plans to ditch synthetic colors are General Mills, Pepsico, ConAgra, Nestle, McCormick, Tyson Foods, Sam's Club, JM Smucker, Hershey, and Kraft Heinz. In-N-Out confirmed to Nexstar's KLTA in May that it was removing artificial coloring from some items.
Nonetheless, relying on voluntary action rather than regulatory requirements won't guarantee compliance, said Thomas Galligan, a scientist with the Center for Science in the Public Interest, a consumer advocacy group.
'Talk is cheap,' Galligan said. 'It's easy for companies to make promises to look like they're being compliant and generate goodwill among consumers and the Trump administration, but it remains to be seen if they will actually follow through.'
Not every company is joining in. Mars, which makes Skittles and M&M's, has been a hold-out, according to reports.
Are artificial dyes bad?
Artificial dyes are used widely in U.S. foods. In Canada and in Europe — where synthetic colors are required to carry warning labels — manufacturers mostly use natural substitutes. Several states, including California and West Virginia, have passed laws restricting the use of artificial colors in foods.
Health advocates have long called for the removal of artificial dyes from foods, citing mixed studies indicating they can cause neurobehavioral problems, including hyperactivity and attention issues, in some children. The FDA has maintained that the approved dyes are safe and that 'the totality of scientific evidence shows that most children have no adverse effects when consuming foods containing color additives.'
Which foods contain Red 3, the dye now banned by the FDA?
The FDA currently allows 36 food color additives, including eight synthetic dyes.
Removing dyes from the food supply will not address the chief health problems that plague Americans, said Susan Mayne, a Yale University chronic disease expert and former director of the FDA's food center.
'With every one of their announcements, they're focusing in on something that's not going to accomplish what they say it is,' Mayne said of Kennedy's initiatives. 'Most of these food dyes have been in our food supply for 100 years. … So why aren't they driving toward reductions in things that do drive chronic disease rates?'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
JPMorgan Cuts Sarepta (SRPT) PT, Keeps Overweight Rating
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On July 10, JPMorgan lowered its price target for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) from $30 to $28 but kept an 'Overweight' rating. JPMorgan highlighted that there is a 'valuation disconnect' and the current stock price does not fully reflect the long-term value of the company's business. A laboratory technician in a white coat holding a microscope and examining a vial of biopharmaceuticals. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has three FDA-approved treatments for Duchenne Muscular Dystrophy (DMD) with amenable mutations. These treatments are known as Exondys 51, Vyondys 53, and Amondys 45. Additionally, JPMorgan analysts noted that the company's gene therapy, Elevidys, has full approval for use in all ambulatory DMD patients. The company's gene therapy Elevidys currently has full approval for all ambulatory DMD patients, according to JPMorgan. However, Elevidys still holds accelerated approval status while Sarepta Therapeutics, Inc. (NASDAQ:SRPT) continues discussions with the FDA. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a medical research and drug development company focused on developing precision genetic medicines for rare diseases. The company has leading positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs). While we acknowledge the potential of SRPT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


CNBC
an hour ago
- CNBC
Whoop says FDA is ‘overstepping its authority' with warning about blood pressure feature
CNBC's Brandon Gomez joins 'Squawk on the Street' to discuss FDA scrutiny over Whoop's blood pressure monitoring tech.


Business Wire
2 hours ago
- Business Wire
Nalu Medical Achieves National Payer Milestone with Aetna Coverage for PNS Therapy
CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc., a leader in miniaturized neuromodulation therapies, is pleased to announce that Aetna Inc. has issued an updated medical policy designating the Nalu Neurostimulation System as medically necessary for the treatment of chronic pain of peripheral nerve origin. This change, effective July 31, 2025, marks a critical milestone in Nalu's mission to expand access to safe, innovative, drug-free alternatives for chronic pain relief. This policy shift moves Nalu from its prior classification of 'Investigational/Experimental' to 'Medically Necessary' for eligible patients—opening access to more than 22 million additional covered lives across the U.S. 'Aetna's recognition of Nalu as a medically necessary therapy is a powerful validation of our technology, clinical evidence, and commitment to patient outcomes,' said Tom West, Chief Executive Officer of Nalu Medical. 'We've built a robust body of clinical data demonstrating that Nalu PNS provides safe, effective, and durable relief for patients living with chronic, intractable pain, as well as healthcare economic data that demonstrates use of Nalu PNS results in significant cost savings. We're proud to see a leading payer like Aetna acknowledge that value, and we look forward to engaging with other health plans to expand access to this life-changing therapy.' Chronic peripheral nerve pain is often debilitating and unresponsive to conventional therapies, including long-term medication and surgery. The Nalu Neurostimulation System offers a minimally invasive, drug-free alternative that delivers precise electrical stimulation to targeted peripheral nerves, providing long-lasting relief while reducing the risks of opioid dependency and avoiding systemic side effects. About the Nalu Neurostimulation System The Nalu System consists of a fully featured, battery-free, miniaturized implantable pulse generator (IPG) 1 that is powered wirelessly by an externally worn Therapy Disc and controlled through a smartphone-based remote control app. Despite its small size, the Nalu micro-IPG™ delivers treatment capabilities similar to larger IPGs as well as advantages associated with advanced waveforms, extensive programming options, exceptional upgradability, and an expected service life of 18 years. The Nalu Neurostimulation System has been repeatedly recognized for its revolutionary technology, including being named as one of the world's top 100 new products by R&D Magazine in 2021 and ranking number 19 in the 2023 Deloitte Technology Fast 500. It is FDA-cleared for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications. To learn more, visit About Nalu Medical, Inc. Nalu is a Carlsbad, California-based medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic neuropathic pain. The Nalu Neurostimulation System delivers gentle electrical pulses to the nervous system to modulate pain signals before they get to the brain. The Nalu Neurostimulation System was designed to address major unmet needs in the treatment of chronic neuropathic pain and provide a differentiated value proposition for patients and physicians. [1] Data on file, Nalu Medical, Inc. 2025.